During the past decade, Udon Thani Cancer Hospital conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Udon Thani Cancer Hospital" #1 collaborator was "Meddoc" with 2 trials as a collaborator and "Norwegian University of Life Sciences" with 2 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Udon Thani Cancer Hospital" are "Metastatic Breast Cancer" (2 trials) and "Stage IV Breast Cancer" (2 trials). Many other conditions were trialed in "Udon Thani Cancer Hospital" in a lesser frequency.

Most popular intervention types in "Udon Thani Cancer Hospital" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "BP-C1" (2 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Udon Thani Cancer Hospital" are 2 trials for "Female" genders.

Currently, there are NaN active trials in "Udon Thani Cancer Hospital". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Udon Thani Cancer Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Udon Thani Cancer Hospital, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".